SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Barnes, E, Goodyear, C.S, Gaskell, C, I de Silva, T, Murray, S.M, Rea, D, Snowden, J.A, Carroll, M, Bowden, S.J, Richter, A, Lim, Z, Satsangi, J, Cook, G, Harrison, M, Lim, S.H, Miller, P, Richter, A.G, Mentzer, A, Jamsen, A, Brown, A, Conlon, C, Dold, C, Skelly, D, Kronsteiner, B, Abraham, P, Phillips, E, Jeffery, K, Frending, L, Stafford, L, Ali, M, Travis, S, Gardiner, S, Dobson, S.L, Faustini, S, Foulkes, S, Frater, J, Hall, V, Hopkins, S, Islam, J, Lambe, T, Moore, S.C, Otter, A, Rowland-Jones, S.L, Wootton, D.G, Irwin, S, Marjot, T, Prendecki, M, Mortimer, P, McIntyre, S, Selby, R, Tipton, T, Orchard, K, Kearns, P, Kirkham, A, Churchill, V, Loughton, H, MacDonald, E, Middleton, G, Billingham, L, Magwaro, S, Arnott, M, Bennett, L, Brock, J, Melville, A, Melville, L, Miller, S, Najm, A, Paterson, C, Rodgers, L, Rutherford, M, Smith, E, Sunzini, F, Crawley, C, Lockey, S, Uttenthal, B, Kesavan, M, Moore, C, Manousou, P, Hahn, G, Mullish, B, Atta, M, Gleeson, S, Lightstone, L, Martin, P, McAdoo, S, Thomson, T, Avenoso, D, Bhandal, K, Trivedi, P, Publicover, A, Scouse, K, Chalk, J, Hanke, D, Healy, S, Provine, N, Thomas, S, Walker, V, Win, Z, Hutchison, C, Richardson, D
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels (
DOI:10.1038/s41591-023-02414-4